Published in Drug Week, July 8th, 2005
Cooper, who has more than 25 years of experience in the pharmaceutical industry, joins Pharmacyclics as a member of the management team and will be responsible for leading the business development activities at Pharmacyclics.
Additionally, the company's board of directors approved a grant to Cooper of a nonqualified stock option to purchase 100,000 shares of Pharmacyclics' common stock.
This option award was granted without stockholder approval pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.